Pharmaceuticals

ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026

HSINCHU, Aug. 25, 2026 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing Asia 2026, taking place September 9–11 at the Marina Bay Sands Expo & Convention Centre in Sin...

2026-08-25 09:15 926

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-08-25 08:30 1316

INDONESIAN HEALTHCARE TRAVEL TO MALAYSIA HITS RECORD RM2.2 BILLION AS MHX RETURNS TO YOGYAKARTA

YOGYAKARTA, Indonesia, Aug. 24, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) once again strengthened Malaysia's presence in Indonesia through MHX Yogyakarta 2026, held from 20 to 23 August 2026 at the Grand Atrium, Pakuwon Mall Jogja. The four-day event came on the back of a rec...

2026-08-24 13:31 1634

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-08-24 09:00 2368

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of ...

2026-08-24 08:00 1466

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic growth momentum and sustainable earnings generation, with revenue reaching RMB 3.5882 billion, a 27.3% ...

2026-08-21 21:50 17886

3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable to equity holders of the Company rea...

2026-08-21 15:39 5038

Sunshine Guojian Releases 2026 Interim Report:

Innovation-driven, Steady Advancement SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sunshine Guojian", stock code: 688336.SH), a pioneer in China's antibody therapeutics, released its 2026 interim report. In the f...

2026-08-21 08:00 3714

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution Conference Cal...

2026-08-21 07:10 3530

inFlow Inventory launches lot number and expiry date tracking

Small manufacturers and distributors in food, beverage, pharmaceutical and medical device industries can now trace any batch from receipt to customer, at a fraction of the cost of an enterprise ERP. TORONTO, Aug. 21, 2026 /PRNewswire/ -- inFlow Inventory has launched lot number and expiry date ...

2026-08-20 23:31 1846

Apollo Hospitals launches 'Always Open, Always Here', a global first in healthcare from India

NEW DELHI, Aug. 20, 2026 /PRNewswire/ -- Apollo Hospitals launched 'Always Open. Always Here.', a first-of-its-kind initiative that makes routine and planned healthcare services available across all seven days of the week, including Sundays.

2026-08-20 22:11 1791

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance[1]: Double-digit revenue growth and gross margin imp...

2026-08-20 08:02 2683

Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Announce Liquid Biopsy Screening Collaboration in Lung Cancer

oncoReveal® Essential+ validated at LSI Medience for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026 NATICK, Mass. and TOKYO, Aug. 20, 2026 /PRNewswire/ -- Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medie...

2026-08-20 06:00 2037

XtalPi Holdings Announces 2026 Interim Results

SHENZHEN, China, Aug. 19, 2026 /PRNewswire/ --  Financial Highlights: * In the first half of 2026, the Group recorded revenue of RMB393.6 million, compared with RMB517.1 million in the corresponding period of last year. The change was primarily attributable to the high base in the correspondin...

2026-08-19 21:19 2326

DrFirst Receives Frost & Sullivan's 2026 North America Enabling Technology Leadership Recognition for Advancing AI-Enhanced Medication Orchestration

DrFirst is honored for redefining medication management with its scalable platform that embeds intelligence directly in prescribing, making it more efficient for providers, pharmacies, and patients. SAN ANTONIO, Aug. 19, 2026 /PRNewswire/ -- As healthcare organizations continue to navigate fragm...

2026-08-19 21:00 1617

ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights

The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care. JENA, Germany, Aug. 19, 2026 /PRNewswire/ -- ZEISS Medical Tech...

2026-08-19 21:00 1837

Sisram Medical Delivers Solid 2026 Interim Results

Injectables Business Fuels Rapid Growth as APAC Drives International Revenue Expansion HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy...

2026-08-19 20:00 2241

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Scie...

2026-08-19 19:45 2406

Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The performance reflected continued strong commercial momentum, dr...

2026-08-19 14:48 850

Everest Medicines Announces Interim Results for First Half of 2026

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first hal...

2026-08-19 11:39 2068
12345 ... 183